BioCentury
ARTICLE | Company News

Sigma-Tau, Soligenix sales and marketing update

January 7, 2013 8:00 AM UTC

Soligenix announced on Dec. 27, 2012, that Sigma-Tau returned North American and European commercialization rights to beclomethasone dipropionate (BDP). Sigma-Tau remains eligible for up to $6 million in regulatory and commercialization milestone payments, plus 3% royalties on sales in North America and Europe, as well as 15% of all upfront payments, milestones and other considerations received by Soligenix from potential partners or licensees. ...